Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ASSESSMENT OF MALIGNANCY OF GLIOMA BY POSITRON-EMISSION-TOMOGRAPHY WITH F-18 FLUORODEOXYGLUCOSE AND SINGLE-PHOTON EMISSION COMPUTED-TOMOGRAPHY WITH TL-201 CHLORIDE
Autore:
TAMURA M; SHIBASAKI T; ZAMA A; KURIHARA H; HORIKOSHI S; ONO N; ORIUCHI N; HIRANO T;
Indirizzi:
GUNMA UNIV,SCH MED,DEPT NEUROSURG,3-39-22 SHOWA MACHI MAEBASHI GUMMA 371 JAPAN GUNMA UNIV,SCH MED,DEPT NUCL MED MAEBASHI GUMMA 371 JAPAN
Titolo Testata:
Neuroradiology
fascicolo: 4, volume: 40, anno: 1998,
pagine: 210 - 215
SICI:
0028-3940(1998)40:4<210:AOMOGB>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
BROMODEOXYURIDINE LABELING INDEX; BRAIN-TUMORS; GLIOBLASTOMA-MULTIFORME; F-18 FLUORODEOXYGLUCOSE; PROGNOSTIC IMPLICATIONS; STEREOTAXIC BIOPSY; CEREBRAL GLIOMAS; TL-201 SPECT; ASTROCYTOMAS; GRADE;
Keywords:
GLIOMA, GRADING; BROMODEOXYURIDINE LABELING INDEX; F-18 FLUORODEOXYGLUCOSE; TL-201 CHLORIDE; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
26
Recensione:
Indirizzi per estratti:
Citazione:
M. Tamura et al., "ASSESSMENT OF MALIGNANCY OF GLIOMA BY POSITRON-EMISSION-TOMOGRAPHY WITH F-18 FLUORODEOXYGLUCOSE AND SINGLE-PHOTON EMISSION COMPUTED-TOMOGRAPHY WITH TL-201 CHLORIDE", Neuroradiology, 40(4), 1998, pp. 210-215

Abstract

The histological diagnosis and proliferative potential measured by bromodeoxyuridine (BrdU) labelling index (LI) were corelated with preoperative CT and contrast-enhanced, MRI, F-18-flurodeoxyglucose positron emission tomography (PET) and (201)T1 single photon emission computed tomography (SPECT) in 43 patients with various grades of glioma. (201)T1 SPECT had slightly higher sensitivity to tumours with BrdU LI greater than or equal to 5 % (showing 10/10) than F-18-FDG PET (7/8 tumours). F-18-FDG PET was better for identifying tumours of BrdU LI < 1% (13/15) than (201)T1 SPECT (13/22). Accumulation of (201)T1 in the tumourwas slightly different from contrast enhancement on CT and/or MRI, and gave ''false-postive'' results in some low-grade gliomas. However, (201)T1 SPECT, which is available in many hospitals and may cost less, provided useful information to supplement that from CT and MRI.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 23:29:30